LifeTimes Online  
Blue Cross Blue Shield
March-April 2012, Vol. XXVII, No. 2
 
Front Page
 
Getting enough sleep
Generic OTC drugs
Medicine cabinet 'must-haves'
How to dispose of medicines
Dealing with angina
'Sandwich generation' stress
Watch for eye diseases
Heart-healthy oils and spreads
Walk for exercise
Tips for healthy hair
 
Risks of raw milk
Coffee and depression
New drug for macular degeneration
FDA approves Juvisync
 
A 'model' hobby
Add joy to your life
New museum showcases Greek history
'Grannies on Safari'
 
 
Medicare Basics
Recent News
About LifeTimes Newsletter
Current Issue
Previous Issues
 


  facebook twitter youtube
  Learn more

 
Share |
Health Briefs

FDA approves new therapy for macular degeneration

The U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) for treating wet, age-related macular degeneration (AMD). The eye condition, which can include the growth of abnormal blood vessels that leak fluid into the retina, can gradually destroy the central vision field.

Edward Cox, M.D., an FDA director, says approval of Eylea provides "an important new treatment option" for those with wet AMD. According to the FDA, the disorder is a leading cause of vision loss among people age 60 and older.

The prescription drug is injected into the eye by an ophthalmologist either every four or eight weeks. It was determined to be safe and effective in maintaining or improving visual acuity on the basis of two clinical trials involving 2,412 adults with wet AMD.

The most common side effects reported by patients during the trials included eye pain, blood at the injection site, floating spots in the field of vision, clouding of the eye lens, and increased eye pressure. The FDA notes that Eylea is not suitable for persons suffering from eye infections or inflammation.

Between 2000 and 2006 the FDA approved several other injectable drugs to treat wet AMD, including Visudyne (verteporfin), Macugen (pegaptanib sodium) and Lucentis (ranibizumab).


A Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association.

© Copyright 2012. . All Rights Reserved.
Home | Important Information